In the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency (AIPRI) trial, a three-year multicenter RCT, 583 patients without diabetes mellitus and with baseline proteinuria (mean urinary protein excretion of 1.8 g/day) were randomly assigned to receive benazepril or placebo. The gene discussed is ACE; the disease is diabetes mellitus.